Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.